Single User License
INR 269960
Site License
INR 539920
Corporate User License
INR 809880

Service Tax Additional

select a format
Price

Single User License
USD 4000
Site License
USD 8000
Corporate User License
USD 12000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2016

Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2016


  Request for Sample Report

Executive Summary

Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, "Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2016" provides an overview of Liver Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Liver Cancer Diagnostic Tests under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons To Buy

The report enables you to

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 9

2.1 Liver Cancer Diagnostic Tests Overview 9

3 Products under Development 10

3.1 Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 10

3.2 Liver Cancer Diagnostic Tests-Pipeline Products by Territory 11

3.3 Liver Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 12

3.4 Liver Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 13

4 Liver Cancer Diagnostic Tests-Pipeline Products under Development by Companies 14

4.1 Liver Cancer Companies-Pipeline Products by Stage of Development 14

4.2 Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 16

5 Liver Cancer Diagnostic Tests Companies and Product Overview 18

5.1 Abbott Diagnostics Company Overview 18

5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18

5.2 Abcodia Ltd. Company Overview 23

5.2.1 Abcodia Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23

5.3 AXO Science S.A.S. Company Overview 24

5.3.1 AXO Science S.A.S. Pipeline Products & Ongoing Clinical Trials Overview 24

5.4 BioMark Technologies Inc. Company Overview 27

5.4.1 BioMark Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 27

5.5 China Sky One Medical, Inc. Company Overview 28

5.5.1 China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28

5.6 Digna Biotech, S.L. Company Overview 29

5.6.1 Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview 29

5.7 Drexel University Company Overview 31

5.7.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview 31

5.8 German Cancer Research Center Company Overview 33

5.8.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 33

5.9 Glycotest, Inc. Company Overview 34

5.9.1 Glycotest, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34

5.10 Imperial College London Company Overview 35

5.10.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 35

5.11 IntegraGen SA Company Overview 36

5.11.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 36

5.12 Matrix-Bio, Inc. Company Overview 38

5.12.1 Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38

5.13 NanoString Technologies, Inc. Company Overview 40

5.13.1 NanoString Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40

5.14 National Cancer Institute Company Overview 42

5.14.1 National Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview 42

5.15 Oncimmune (USA) LLC Company Overview 44

5.15.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 44

5.16 Orion Genomics LLC Company Overview 45

5.16.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45

5.17 PleX Diagnostics Company Overview 46

5.17.1 PleX Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 46

5.18 ProMIS Neurosciences Inc. Company Overview 47

5.18.1 ProMIS Neurosciences Inc. Pipeline Products & Ongoing Clinical Trials Overview 47

5.19 Proplex Technologies, Llc Company Overview 49

5.19.1 Proplex Technologies, Llc Pipeline Products & Ongoing Clinical Trials Overview 49

5.20 Proteome Sciences Plc Company Overview 50

5.20.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 50

5.21 Roche Diagnostics International Ltd. Company Overview 52

5.21.1 Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview 52

5.22 TrovaGene, Inc. Company Overview 53

5.22.1 TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53

5.23 University of Rochester Company Overview 55

5.23.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 55

5.24 Ventana Medical Systems, Inc. Company Overview 56

5.24.1 Ventana Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56

5.25 Viomics Inc. Company Overview 57

5.25.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 57

5.26 XEPTAGEN SpA Company Overview 58

5.26.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 58

5.27 Xiamen Zeesan Biotech Co.,Ltd Company Overview 63

5.27.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

6 Liver Cancer Diagnostic Tests-Recent Developments 64

6.1 Aug 12, 2016: ProMIS Neurosciences Announces Second Quarter 2016 Results 64

6.2 Aug 09, 2016: Blueprint Medicines Reports Second Quarter 2016 Financial Results 65

6.3 Aug 04, 2016: Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments 66

6.4 Aug 04, 2016: PerkinElmer Announces Financial Results for the Second Quarter of 2016 67

6.5 Aug 03, 2016: NanoString Technologies Releases Operating Results for Second Quarter of 2016 68

6.6 Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results 69

6.7 Jul 27, 2016: PerkinElmer Elects Frank Witney to Board of Directors 74

6.8 Jul 13, 2016: Pfizer and NovaMedica announce a strategic partnership in Russia 74

6.9 Jul 12, 2016: PerkinElmer Raises USD552.3 Million in Public Offering of 1.875% Senior Notes Due 2026 75

6.10 Jul 07, 2016: IntegraGen reports strong revenue growth during first half of 2016 76

6.11 Jul 04, 2016: Oncimmune Enters into Research Agreement with Egybiotech and Aarhus University Hospital 76

6.12 Jun 27, 2016: ProMIS Neurosciences Raises USD0.8 Million in Private Placement of Units 76

6.13 Jun 23, 2016: Oncimmune Appoints Julian Hirst as Non-Executive Director 77

6.14 Jun 16, 2016: Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts 77

6.15 Jun 02, 2016: NanoString Technologies Highlights Advances in Precision Oncology and Immunotherapy at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) 78

6.16 Jun 01, 2016: Royal Philips Enters into Research Agreement with Yale School of Medicine 81

6.17 Jun 01, 2016: Proteome Sciences Announces CEO Appointment 81

6.18 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 82

6.19 May 31, 2016: Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 82

6.20 May 31, 2016: Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 83

6.21 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 83

6.22 May 31, 2016: Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 84

6.23 May 11, 2016: ProMIS Neurosciences announces first quarter 2016 results 84

6.24 May 10, 2016: Trovagene Announces First Quarter 2016 Financial Results 85

6.25 May 10, 2016: Blueprint Medicines Reports First Quarter 2016 Financial Results 86

6.26 Apr 27, 2016: A.G. Schneiderman Announces Multistate And Federal Settlement With Wyeth And Pfizer For USD 784.6m To Resolve Allegations Of Underpaying Rebates Owed Through The Medicaid Drug Rebate Program 88

6.27 Mar 07, 2016: Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems 89

6.28 Dec 02, 2015: Surefire Medical Raises USD15 Million in Series C Financing 89

6.29 Oct 27, 2015: Simple blood test measures risk of liver cancer 89

6.30 Sep 21, 2015: Veran Medical Raises USD30.6 Million in Venture Financing 90

6.31 Sep 09, 2015: Quirem Medical Raises Funds through Private Placement of Shares 90

7 Appendix 91

7.1 Methodology 91

7.2 About GlobalData 93

7.3 Contact Us 94

7.4 Disclaimer 94

1.2 List of Figures

Figure 1: Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 10

Figure 2: Liver Cancer Diagnostic Tests-Pipeline Products by Territory 11

Figure 3: Liver Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 12

Figure 4: Liver Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 13

1.1 List of Tables

Table 1: Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 10

Table 2: Liver Cancer Diagnostic Tests-Pipeline Products by Territory 11

Table 3: Liver Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 12

Table 4: Liver Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 13

Table 5: Liver Cancer Diagnostic Tests Companies-Pipeline Products by Stage of Development 14

Table 6: Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 16

Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18

Table 8: ARCHITECT c16000 System-PIVKA Assay-Product Status 18

Table 9: ARCHITECT c16000 System-PIVKA Assay-Product Description 19

Table 10: ARCHITECT c4000 System-PIVKA Assay-Product Status 19

Table 11: ARCHITECT c4000 System-PIVKA Assay-Product Description 19

Table 12: ARCHITECT c8000 System-PIVKA Assay-Product Status 20

Table 13: ARCHITECT c8000 System-PIVKA Assay-Product Description 20

Table 14: ARCHITECT ci16200 Integrated System-PIVKA Assay-Product Status 20

Table 15: ARCHITECT ci16200 Integrated System-PIVKA Assay-Product Description 21

Table 16: ARCHITECT ci4100 Integrated System-PIVKA Assay-Product Status 21

Table 17: ARCHITECT ci4100 Integrated System-PIVKA Assay-Product Description 21

Table 18: ARCHITECT ci8200 Integrated System-PIVKA Assay-Product Status 22

Table 19: ARCHITECT ci8200 Integrated System-PIVKA Assay-Product Description 22

Table 20: Abcodia Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23

Table 21: Biomarker Test-Liver Cancer-Product Status 23

Table 22: Biomarker Test-Liver Cancer-Product Description 23

Table 23: AXO Science S.A.S. Pipeline Products & Ongoing Clinical Trials Overview 24

Table 24: Multiplexed Detection-Des-Carboxy Prothrombin-Product Status 24

Table 25: Multiplexed Detection-Des-Carboxy Prothrombin-Product Description 25

Table 26: Multiplexed Detection-Matrix metalloproteinase 1-Product Status 25

Table 27: Multiplexed Detection-Matrix metalloproteinase 1-Product Description 25

Table 28: Multiplexed Detection-Procollagen type III N-terminal peptide-Product Status 26

Table 29: Multiplexed Detection-Procollagen type III N-terminal peptide-Product Description 26

Table 30: BioMark Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 27

Table 31: Biomarker Assay-Hepatocellular Cancer-Product Status 27

Table 32: Biomarker Assay-Hepatocellular Cancer-Product Description 27

Table 33: China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28

Table 34: Diagnostic Kit-Liver Cancer-Product Status 28

Table 35: Diagnostic Kit-Liver Cancer-Product Description 28

Table 36: Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview 29

Table 37: HCC Molecular Marker Assay-Product Status 29

Table 38: HCC Molecular Marker Assay-Product Description 29

Table 39: Oxidated APO-A1 Assay-Product Status 30

Table 40: Oxidated APO-A1 Assay-Product Description 30

Table 41: Drexel University Pipeline Products & Ongoing Clinical Trials Overview 31

Table 42: Diagnostic Test-Liver Cancer-Product Status 31

Table 43: Diagnostic Test-Liver Cancer-Product Description 31

Table 44: Glycan-Based Biomarker Assay-Liver Cancer-Product Status 32

Table 45: Glycan-Based Biomarker Assay-Liver Cancer-Product Description 32

Table 46: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 33

Table 47: RAGE Based Diagnostic Assay-Liver Cancer-Product Status 33

Table 48: RAGE Based Diagnostic Assay-Liver Cancer-Product Description 33

Table 49: Glycotest, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34

Table 50: Diagnostic Test-Liver Cancer-Product Status 34

Table 51: Diagnostic Test-Liver Cancer-Product Description 34

Table 52: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 35

Table 53: Diagnostic Assay-HCC-Product Status 35

Table 54: Diagnostic Assay-HCC-Product Description 35

Table 55: IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 36

Table 56: CLIA Test-Hepatocellular Carcinoma-Product Status 36

Table 57: CLIA Test-Hepatocellular Carcinoma-Product Description 37

Table 58: Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38

Table 59: VeraMarker LCS (Liver Cancer Screening) Test-Product Status 38

Table 60: VeraMarker LCS (Liver Cancer Screening) Test-Product Description 38

Table 61: VeraMarker Liver Cancer Screening Test-Hepatitis-Product Status 39

Table 62: VeraMarker Liver Cancer Screening Test-Hepatitis-Product Description 39

Table 63: NanoString Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40

Table 64: In Vitro Diagnostic Assay-HCC Gene Signature-Product Status 40

Table 65: In Vitro Diagnostic Assay-HCC Gene Signature-Product Description 41

Table 66: National Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview 42

Table 67: HCC Gene Signature Diagnostic Test-Product Status 42

Table 68: HCC Gene Signature Diagnostic Test-Product Description 42

Table 69: HCC Gene Signature Prognostic Test-Product Status 43

Table 70: HCC Gene Signature Prognostic Test-Product Description 43

Table 71: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 44

Table 72: EarlyCDT-Liver Cancer-Product Status 44

Table 73: EarlyCDT-Liver Cancer-Product Description 44

Table 74: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45

Table 75: Diagnostic Assay-Liver Cancer-Product Status 45

Table 76: Diagnostic Assay-Liver Cancer-Product Description 45

Table 77: PleX Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 46

Table 78: HCCpleX-Product Status 46

Table 79: HCCpleX-Product Description 46

Table 80: ProMIS Neurosciences Inc. Pipeline Products & Ongoing Clinical Trials Overview 47

Table 81: Screening Test-Liver Cancer-Product Status 47

Table 82: Screening Test-Liver Cancer-Product Description 48

Table 83: Proplex Technologies, Llc Pipeline Products & Ongoing Clinical Trials Overview 49

Table 84: Biomarker Diagnostic Test-Liver Cancer-Product Status 49

Table 85: Biomarker Diagnostic Test-Liver Cancer-Product Description 49

Table 86: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 50

Table 87: Biomarker Assay-Liver Cancer-Product Status 50

Table 88: Biomarker Assay-Liver Cancer-Product Description 51

Table 89: Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview 52

Table 90: Glypican-3 MAb Companion Diagnostic Test-Product Status 52

Table 91: Glypican-3 MAb Companion Diagnostic Test-Product Description 52

Table 92: TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53

Table 93: Diagnostic Test-Liver Cancer-Product Status 53

Table 94: Diagnostic Test-Liver Cancer-Product Description 54

Table 95: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 55

Table 96: Biomarker Test-HCC-Product Status 55

Table 97: Biomarker Test-HCC-Product Description 55

Table 98: Ventana Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56

Table 99: BLU-554 Companion Diagnostic Assay-Hepatocellular Carcinoma-Product Status 56

Table 100: BLU-554 Companion Diagnostic Assay-Hepatocellular Carcinoma-Product Description 56

Table 101: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 57

Table 102: Diagnostic Assay-Liver Cancer-Product Status 57

Table 103: Diagnostic Assay-Liver Cancer-Product Description 57

Table 104: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 58

Table 105: compleXima HCC Biochip-Liver Cancer-Product Status 58

Table 106: compleXima HCC Biochip-Liver Cancer-Product Description 59

Table 107: DCP-IgM Kit-Liver Cancer-Product Status 59

Table 108: DCP-IgM Kit-Liver Cancer-Product Description 59

Table 109: GPC3-IgM Kit-Liver Cancer-Product Status 60

Table 110: GPC3-IgM Kit-Liver Cancer-Product Description 60

Table 111: Osteopontin-IgM Kit-Liver Cancer-Product Status 60

Table 112: Osteopontin-IgM Kit-Liver Cancer-Product Description 61

Table 113: Survivin-IgM Kit-Liver Cancer-Product Status 61

Table 114: Survivin-IgM Kit-Liver Cancer-Product Description 61

Table 115: VEGF-IgM Kit-Liver Cancer-Product Status 62

Table 116: VEGF-IgM Kit-Liver Cancer-Product Description 62

Table 117: Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

Table 118: Theranostic-Liver Cancer Metastasis-Product Status 63

Table 119: Theranostic-Liver Cancer Metastasis-Product Description 63

Table 120: Glossary 92

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abbott Diagnostics

Abcodia Ltd.

AXO Science S.A.S.

BioMark Technologies Inc.

China Sky One Medical, Inc.

Digna Biotech, S.L.

Drexel University

German Cancer Research Center

Glycotest, Inc.

Imperial College London

IntegraGen SA

Matrix-Bio, Inc.

NanoString Technologies, Inc.

National Cancer Institute

Oncimmune (USA) LLC

Orion Genomics LLC

PleX Diagnostics

ProMIS Neurosciences Inc.

Proplex Technologies, Llc

Proteome Sciences Plc

Roche Diagnostics International Ltd.

TrovaGene, Inc.

University of Rochester

Ventana Medical Systems, Inc.

Viomics Inc.

XEPTAGEN SpA

Xiamen Zeesan Biotech Co.,Ltd

Abbott Diagnostics, ARCHITECT c16000 System-PIVKA Assay; Abbott Diagnostics, ARCHITECT c4000 System-PIVKA Assay; Abbott Diagnostics, ARCHITECT c8000 System-PIVKA Assay; Abbott Diagnostics, ARCHITECT ci16200 Integrated System-PIVKA Assay; Abbott Diagnostics, ARCHITECT ci4100 Integrated System-PIVKA Assay; Abbott Diagnostics, ARCHITECT ci8200 Integrated System-PIVKA Assay; Abcodia Ltd., Biomarker Test-Liver Cancer; AXO Science S.A.S., Multiplexed Detection-Des-Carboxy Prothrombin; AXO Science S.A.S., Multiplexed Detection-Matrix metalloproteinase 1; AXO Science S.A.S., Multiplexed Detection-Procollagen type III N-terminal peptide; BioMark Technologies Inc., Biomarker Assay-Hepatocellular Cancer; China Sky One Medical, Inc., Diagnostic Kit-Liver Cancer; Digna Biotech, S.L., HCC Molecular Marker Assay; Digna Biotech, S.L., Oxidated APO-A1 Assay; Drexel University, Diagnostic Test-Liver Cancer; Drexel University, Glycan-Based Biomarker Assay-Liver Cancer; German Cancer Research Center, RAGE Based Diagnostic Assay-Liver Cancer; Glycotest, Inc., Diagnostic Test-Liver Cancer; Imperial College London, Diagnostic Assay-HCC; IntegraGen SA, CLIA Test-Hepatocellular Carcinoma; Matrix-Bio, Inc., VeraMarker LCS (Liver Cancer Screening) Test; Matrix-Bio, Inc., VeraMarker Liver Cancer Screening Test-Hepatitis; NanoString Technologies, Inc., In Vitro Diagnostic Assay-HCC Gene Signature; National Cancer Institute, HCC Gene Signature Diagnostic Test; National Cancer Institute, HCC Gene Signature Prognostic Test; Oncimmune (USA) LLC, EarlyCDT-Liver Cancer; Orion Genomics LLC, Diagnostic Assay-Liver Cancer; PleX Diagnostics, HCCpleX; ProMIS Neurosciences Inc., Screening Test-Liver Cancer; Proplex Technologies, Llc, Biomarker Diagnostic Test-Liver Cancer; Proteome Sciences Plc, Biomarker Assay-Liver Cancer; Roche Diagnostics International Ltd., Glypican-3 MAb Companion Diagnostic Test; TrovaGene, Inc., Diagnostic Test-Liver Cancer; University of Rochester, Biomarker Test-HCC; Ventana Medical Systems, Inc., BLU-554 Companion Diagnostic Assay-Hepatocellular Carcinoma; Viomics Inc., Diagnostic Assay-Liver Cancer; XEPTAGEN SpA, compleXima HCC Biochip-Liver Cancer; XEPTAGEN SpA, DCP-IgM Kit-Liver Cancer; XEPTAGEN SpA, GPC3-IgM Kit-Liver Cancer; XEPTAGEN SpA, Osteopontin-IgM Kit-Liver Cancer; XEPTAGEN SpA, Survivin-IgM Kit-Liver Cancer; XEPTAGEN SpA, VEGF-IgM Kit-Liver Cancer; Xiamen Zeesan Biotech Co.,Ltd, Theranostic-Liver Cancer Metastasis


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com